<PAGE>
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): DECEMBER 5, 1997
AMGEN INC.
(Exact Name of Registrant as Specified in Charter)
<TABLE>
<S> <C> <C>
DELAWARE 0-12477 95-3540776
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
</TABLE>
1840 DEHAVILLAND DRIVE
THOUSAND OAKS, CALIFORNIA 91320-1789
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (805) 447-1000
NOT APPLICABLE
(Former Name or Former Address, if Changed Since Last Report)
- --------------------------------------------------------------------------------
<PAGE>
ITEM 5. OTHER EVENTS.
On November 18, 1997, Amgen Inc. (the "Company") filed with the Securities
and Exchange Commission (the "Commission") a registration statement on Form S-3
(File No. 333-40405) (the "Registration Statement") under the Securities Act of
1933, as amended (the "Securities Act"), relating to the public offering from
time to time of up to $500,000,000 in aggregate initial offering price of debt
securities of the Company. On November 26, 1997, the Company filed a prospectus
supplement (including the base prospectus dated November 24, 1997 contained
therein) with the Commission pursuant to Rule 424(b) under the Securities Act
relating to the public offering of $100,000,000 principal amount of 6.50% Notes
Due December 1, 2007.
On December 2, 1997, the Company entered into an underwriting agreement
(the "Underwriting Agreement") with Goldman, Sachs & Co. and Bear, Stearns & Co.
Inc. relating to the sale of the Company's 6.50% Notes Due December 1, 2007.
The Underwriting Agreement is attached hereto.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
1.1 Underwriting Agreement, dated December 2, 1997, among Goldman, Sachs & Co.
and Bear, Stearns & Co. Inc. and the Company.
4.1 Officer's Certificate pursuant to Sections 2.1 and 2.3 of the Indenture,
dated as of January 1, 1992, as supplemented by the First Supplemental
Indenture, dated as of February 26, 1997, each between the Company and
Citibank, N.A., as Trustee, establishing a series of securities entitled
"6.50% Notes Due December 1, 2007."
4.2 6.50% Notes Due December 1, 2007 described in Exhibit 4.1.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereto duly authorized.
Amgen Inc.
Dated: December 5, 1997 By /s/ Robert S. Attiyeh
----------------------------
Robert S. Attiyeh
Senior Vice President Finance
and Corporate Development,
and Chief Financial Officer
3
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
- ------ -----------
<C> <S>
1.1 Underwriting Agreement, dated December 2, 1997, among Goldman, Sachs &
Co. and Bear, Stearns & Co. Inc. and the Company.
4.1 Officer's Certificate pursuant to Sections 2.1 and 2.3 of the Indenture,
dated as of January 1, 1992, as supplemented by the First Supplemental
Indenture, dated as of February 26, 1997, each between the Company and
Citibank, N.A., as Trustee, establishing a series of securities entitled
"6.50% Notes Due December 1, 2007."
4.2 6.50% Notes Due December 1, 2007 described in Exhibit 4.1.
</TABLE>
<PAGE>
EXHIBIT 1.1
UNDERWRITING AGREEMENT
December 2, 1997
AMGEN INC.
1840 DeHavilland Drive
Thousand Oaks, California 91320-1789
Ladies and Gentlemen:
We, the underwriters named below (collectively, the "Underwriters"),
understand that Amgen Inc., a Delaware corporation (the "Company"), proposes to
issue and sell $100,000,000 aggregate principal amount of its 6.50% Notes due
December 1, 2007 (the "Offered Securities").
A. Subject to the terms and conditions set forth or incorporated by
reference herein, the Company hereby agrees to sell and the Underwriters agree
to purchase, severally and not jointly, the principal amount of the Offered
Securities set forth below opposite their names at a purchase price of 98.805%
of the principal amount of the Offered Securities, plus accrued interest, if
any, from December 1, 1997 to the Closing Date (as defined below):
<TABLE>
<CAPTION>
Principal Amount of
Name Offered Securities
---- ------------------
<S> <C>
Goldman, Sachs & Co............................. $ 50,000,000
Bear, Stearns & Co. Inc......................... $ 50,000,000
Total........................ $100,000,000
============
</TABLE>
The Underwriters will pay for the Offered Securities upon delivery thereof at
10:00 a.m. (New York time) on December 5, 1997, at such place as the
Underwriters shall designate. Such date and location of delivery of and payment
for the Offered Securities may be varied by agreement between the Company and
the
<PAGE>
Underwriters. The time and date of such payment and delivery are hereinafter
referred to as the Closing Date.
B. The Offered Securities are to be issued pursuant to the
provisions of an Indenture, dated as of January 1, 1992, as supplemented by a
First Supplemental Indenture dated as of February 26, 1997 (as so supplemented,
and including any instrument establishing the form and terms of the Offered
Securities, the "Indenture"), between the Company and Citibank, N.A., as
trustee.
C. The Offered Securities shall have the terms set forth in the
Basic Prospectus dated November 24, 1997, and the Prospectus Supplement dated
December 2, 1997, relating to the Offered Securities.
D. The Company will pay all expenses incident to the performance of
its obligations under this Agreement, including, without limitation, (i) the
preparation, printing (or reproduction) and filing with the Commission of the
Registration Statement, any preliminary prospectus and the Prospectus and of
each amendment and supplement thereto, (ii) the printing (or reproduction) and
delivery to the Underwriters of this Agreement and such other documents as may
be required in connection with the offering, purchase, sale and delivery of the
Offered Securities, (iii) the preparation, issuance and delivery of the
certificates for the Offered Securities to the Underwriters, including any
transfer taxes or duties payable upon the sale of the Offered Securities to the
Underwriters, (iv) the fees and disbursements of the Company's counsel,
accountants and other advisors, (v) the expenses described in Section 5(d)
hereof, and (vi) the printing (or reproduction) and delivery to the Underwriters
of any blue sky survey and any supplement thereto.
E. All provisions contained in the document entitled Amgen Inc.
Underwriting Agreement Standard Provisions (Debt Securities), a copy of which is
attached hereto, are herein incorporated by reference in their entirety and
shall be deemed to be a part of this Agreement to the same extent as if such
provisions had been set forth in full herein, except that (i) if any term
defined in such document is otherwise defined herein, the definition set forth
herein shall control and (ii) all references in such document to a type of
security that is not an Offered Security shall not be deemed to be a part of
this Agreement.
2
<PAGE>
Please confirm your agreement by having an authorized officer sign a
copy of this Agreement in the space set forth below.
Very truly yours,
GOLDMAN, SACHS & CO.
BEAR, STEARNS & CO. INC.
As the Underwriters named herein
By: /s/ Goldman, Sachs & Co.
___________________________________
(GOLDMAN, SACHS & CO.)
Accepted:
AMGEN INC.
By: /s/ Robert S. Attiyeh
_____________________________
Name: Robert S. Attiyeh
Title: Senior Vice President,
Finance and Corporate
Development
3
<PAGE>
AMGEN INC.
UNDERWRITING AGREEMENT
STANDARD PROVISIONS
(DEBT SECURITIES)
From time to time, Amgen Inc., a Delaware corporation (the "Company"),
may enter into one or more underwriting agreements that provide for the sale of
designated securities to the several underwriters named therein. The standard
provisions set forth herein may be incorporated by reference in any such
underwriting agreement (each, an "Underwriting Agreement"). Any such
Underwriting Agreement, including the provisions incorporated therein by
reference, is herein referred to as this Agreement. Terms defined in any such
Underwriting Agreement are used herein as therein defined.
The Company has filed with the Securities and Exchange Commission (the
"Commission") a registration statement (Registration No. 333-40405) (as amended
to the date of this Agreement, the "Registration Statement") including a
prospectus relating to the Offered Securities and has filed with, or transmitted
for filing to, or shall promptly hereafter file with or transmit for filing to,
the Commission a prospectus supplement (the "Prospectus Supplement")
specifically relating to the Offered Securities pursuant to Rule 424 under the
Securities Act of 1933, as amended (the "Securities Act"). The term "Basic
Prospectus" means the basic prospectus included in the Registration Statement,
as amended to the date of this Agreement. The term "Prospectus" means the Basic
Prospectus together with the Prospectus Supplement. The term "preliminary
prospectus" means the preliminary prospectus supplement specifically relating to
the Offered Securities, filed with the Commission on November 26, 1997 pursuant
to Rule 424 under the Securities Act, together with the Basic Prospectus. As
used herein, the terms "Basic Prospectus," "Prospectus," "preliminary
prospectus," "supplement" and "amendment" or "amend" shall include, in each
case, all documents that are incorporated or (as required by paragraph (b) of
Item 12 of Form S-3) deemed to be incorporated by reference in the Prospectus
that are filed subsequent to the date of the Basic Prospectus by the Company
with the Commission pursuant to the Securities Exchange Act of 1934, as amended
(the "Exchange Act").
<PAGE>
The term "Significant Subsidiary" shall be used herein as such term is
defined in Rule 1-02 of Regulation S-X.
The term "Subsidiary" as used herein shall mean any corporation the
outstanding securities of which having ordinary voting power to elect a majority
of the board of directors of such corporation (whether or not any other class of
securities has or might have voting power by reason of the happening of a
contingency) are at the time owned or controlled directly or indirectly by the
Company or one or more Subsidiaries or by the Company and one or more
Subsidiaries.
1. Representations and Warranties. The Company represents and
------------------------------
warrants to each of the Underwriters and agrees with each Underwriter that:
(a) The Registration Statement has become effective; no stop
order suspending the effectiveness of the Registration Statement is in
effect, and no proceedings for such purpose are pending before or to the
Company's knowledge threatened by the Commission.
(b) (i) Each document, if any, filed or to be filed pursuant to
the Exchange Act and incorporated by reference in the Prospectus complied
or will comply when so filed in all material respects with the Exchange Act
and the applicable rules and regulations of the Commission thereunder, (ii)
each part of the Registration Statement, when such part became effective,
did not contain, and each such part, as amended or supplemented, if
applicable, will not contain, any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading, (iii) the Registration
Statement and the Prospectus comply, and, as amended or supplemented, if
applicable, will comply, in all material respects with the Securities Act
and the applicable rules and regulations of the Commission thereunder and
(iv) the Prospectus does not contain and, as amended or supplemented, if
applicable, will not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading,
except that the representations and warranties set forth in this Section
1(b) do not apply (A) to statements or omissions in the Registration
Statement or the Prospectus based upon information concerning any
Underwriter furnished to the Company in writing by such Under-
2
<PAGE>
writer expressly for use therein or (B) to that part of the Registration
Statement that constitutes the Statement of Eligibility and Qualification
(Form T-1) under the Trust Indenture Act of 1939, as amended (the "Trust
Indenture Act"), of the trustee referred to in the Registration Statement.
(c) The Company has been duly incorporated, is validly existing
as a corporation in good standing under the laws of the State of Delaware,
has the corporate power and authority to own its property and to conduct
its business as described in the Prospectus and is duly qualified to
transact business and is in good standing in each jurisdiction in which the
conduct of its business or its ownership or leasing of property requires
such qualification, except to the extent that the failure to be so
qualified or be in good standing would not have a material adverse effect
on the financial condition of the Company and its Subsidiaries, taken as a
whole.
(d) The Company has no Significant Subsidiaries.
(e) Kirin-Amgen, Inc. has been duly incorporated, is validly
existing as a corporation in good standing under the laws of the
jurisdiction of its incorporation, has the power and authority to own its
property and to conduct its business as described in the Prospectus and is
duly qualified to transact business and is in good standing in each
jurisdiction in which the conduct of its business or its ownership or
leasing of property requires such qualification, except to the extent that
the failure to be so qualified or be in good standing would not have a
material adverse effect on the financial condition of the Company and its
Subsidiaries, taken as a whole.
(f) This Agreement has been duly authorized, executed and
delivered by the Company.
(g) The Indenture has been duly authorized, executed and
delivered by the Company and (assuming the due execution and delivery
thereof by the trustee thereunder) is a valid and binding agreement of the
Company, enforceable in accordance with its terms except (i) to the extent
that a waiver of rights under any usury laws may be unenforceable and as
the enforceability thereof may be limited by bankruptcy, insolvency,
fraudulent conveyance, moratorium or other similar laws now or hereafter in
effect relating to or affecting the enforcement of creditors' rights and
3
<PAGE>
remedies generally and (ii) as rights of acceleration and the availability
of equitable remedies may be limited by equitable principles of general
applicability, whether or not enforcement is sought at law or in equity.
(h) The Offered Securities have been duly authorized and, when
executed and authenticated in accordance with the provisions of the
Indenture and delivered to and paid for by the Underwriters in accordance
with the terms of this Agreement, will be entitled to the benefits of the
Indenture and will be valid and legally binding obligations of the Company,
enforceable in accordance with their terms except (i) to the extent that a
waiver of rights under any usury laws may be unenforceable and as the
enforceability thereof may be limited by bankruptcy, insolvency, fraudulent
conveyance, moratorium or other similar laws now or hereafter in effect
relating to or affecting the enforcement of creditors' rights and remedies
generally and (ii) as rights of acceleration and the availability of
equitable remedies may be limited by equitable principles of general
applicability, whether or not enforcement is sought at law or in equity.
(i) The execution and delivery by the Company of, and the
performance by the Company of its obligations under, this Agreement, the
Indenture and the Offered Securities (A) will not contravene any provision
of (i) the certificate of incorporation or by-laws of the Company, (ii) any
agreement or other instrument binding upon the Company, Kirin-Amgen, Inc.
or their respective business or assets that is material to the financial
condition of the Company and its Subsidiaries, taken as a whole, (iii)
applicable law and (iv) any judgment, order or decree of any governmental
body, agency or court having jurisdiction over the Company, Kirin-Amgen,
Inc. or their respective business or assets, and (B) no consent, approval
or authorization or order of or qualification with any governmental body or
agency is required for the performance by the Company of its obligations
under this Agreement, the Indenture or the Offered Securities except such
as may be required by the securities or Blue Sky laws of the various states
in connection with the offer and sale of the Offered Securities.
(j) There has not been any material adverse change or any
prospective material adverse change in the financial condition or in the
earnings of the Company and its Subsidiaries, taken as a whole, from that
set forth in the Prospectus.
4
<PAGE>
(k) There are no legal or governmental proceedings pending or to
the Company's knowledge threatened to which the Company or Kirin-Amgen,
Inc. is a party or to which any of their respective properties is subject
that are required to be described in the Registration Statement or the
Prospectus and are not so described or any contracts or other documents
that are required to be filed as exhibits to the Registration Statement
that are not filed as required.
(l) Each of the Company and Kirin-Amgen, Inc. has all necessary
consents, authorizations, approvals, orders, certificates and permits of
and from, and has made all declarations and filings with, all federal,
state, local and other governmental authorities, all self-regulatory
organizations and all courts and other tribunals, to own, lease, license
and use its properties and assets and to conduct its business in the manner
described in the Prospectus, except to the extent that the failure to
obtain or file would not have a material adverse effect on the financial
condition of the Company and its Subsidiaries, taken as a whole.
(m) The Company is not an "investment company" or an entity
"controlled by" an "investment company," as such terms are defined in the
Investment Company Act of 1940, as amended.
(n) To the Company's knowledge, each of the Company and Kirin-
Amgen, Inc. owns or possesses, or can acquire on reasonable terms, all
patents, licenses, inventions, copyrights, know-how (including trade
secrets and other unpatented and/or unpatentable proprietary or
confidential information, systems or procedures), trademarks, service marks
and trade names which are currently employed by them in connection with the
business now operated by them and which, in each case, are material to the
financial condition of the Company and its Subsidiaries, taken as a whole,
and, except as described in the Registration Statement or the Prospectus,
neither the Company nor Kirin-Amgen, Inc. has received any notice of
infringement with respect to any of the foregoing which, singly or in the
aggregate, would reasonably likely result in any material adverse change in
the financial condition of the Company and its Subsidiaries, taken as a
whole.
(o) Neither the Company nor Kirin-Amgen, Inc. is in violation of
any federal or state law or regulation relating to occupational
5
<PAGE>
safety and health or to the storage, handling or transportation of
hazardous or toxic materials and each of the Company and Kirin-Amgen, Inc.
has received all permits, licenses or other approvals required of them
under applicable federal and state occupational safety and health and
environmental laws and regulations to conduct their respective businesses,
and each of the Company and Kirin-Amgen, Inc. is in compliance with all
terms and conditions of any such permit, license or approval, except any
such violation of law or regulation, failure to receive required permits,
licenses or other approvals or failure to comply with the terms and
conditions of such permits, licenses or approvals which would not, singly
or in the aggregate, result in a material adverse change in the financial
condition of the Company and its Subsidiaries, taken as a whole, except as
described in or contemplated by the Prospectus.
2. Public Offering. The Company is advised by the Underwriters that
---------------
the Underwriters propose to make a public offering of their respective portions
of the Offered Securities as soon after this Agreement has been entered into as
in the Underwriters' judgment is advisable. The terms of the public offering of
the Offered Securities are set forth in the Prospectus.
3. Purchase and Delivery. Except as otherwise provided in this
---------------------
Section 3, payment for the Offered Securities shall be made by wire transfer of
same day funds at the time and place set forth in this Agreement, upon delivery
to the respective accounts of the several Underwriters of the Offered
Securities, represented by a fully registered global security and registered in
the name of The Depository Trust Company or its nominee, with any transfer taxes
payable in connection with the transfer of the Offered Securities to the
Underwriters duly paid.
4. Conditions to Closing. The several obligations of the
---------------------
Underwriters hereunder are subject to the following conditions:
(a) (i) subsequent to the execution and delivery of this
Agreement and prior to the Closing Date, there shall not have occurred
any downgrading, nor shall any notice have been given of any intended
or potential downgrading or of any review for a possible change that
does not indicate the direction of the possible change, in the rating
accorded any of the Company's securities by any "nationally recognized
statistical rating organization," as such
6
<PAGE>
term is defined for purposes of Rule 436(g)(2) under the Securities
Act;
(ii) there shall not have occurred any change in the
financial condition or in the earnings of the Company and its
Subsidiaries, taken as a whole, from that set forth in the Prospectus,
that, in the judgment of the Underwriters, is material and adverse and
that makes it, in the judgment of the Underwriters, impracticable to
market the Offered Securities on the terms and in the manner
contemplated in the Prospectus; and
(iii) the Underwriters shall have received on the Closing
Date a certificate, dated the Closing Date and signed by an executive
officer of the Company, to the effect set forth in clause (i) above
and to the effect that the representations and warranties of the
Company contained in this Agreement are true and correct in all
material respects as of the Closing Date and that the Company has
complied in all material respects with all of the agreements and
satisfied all of the conditions on its part to be performed or
satisfied on or before the Closing Date.
The officer signing and delivering such certificate may rely upon
the best of his knowledge as to proceedings threatened.
(b) The Underwriters shall have received on the Closing Date an
opinion of counsel for the Company (who may be an employee of the Company),
dated the Closing Date, to the effect set forth in Exhibit A.
(c) The Underwriters shall have received on the Closing Date an
opinion of Latham & Watkins, special counsel for the Company, dated the
Closing Date, to the effect set forth in Exhibit B.
(d) The Underwriters shall have received on the Closing Date an
opinion of Skadden, Arps, Slate, Meagher & Flom LLP, special counsel for
the Underwriters, dated the Closing Date, to the effect set forth in
Exhibit C.
(e) The Underwriters shall have received at the time of the
execution of this Agreement a letter, dated the date hereof, in form and
7
<PAGE>
substance satisfactory to the Underwriters, from Ernst & Young LLP, the
Company's independent public accountants, containing statements and
information of the type ordinarily included in accountants' "comfort
letters" to underwriters with respect to the financial statements and
certain financial information contained in or incorporated by reference
into the Prospectus.
(f) The Registration Statement shall have become effective and on
the Closing Date no stop order suspending the effectiveness of the
Registration Statement shall have been issued under the Securities Act or
proceedings therefor initiated or, to the knowledge of the Company or the
Underwriters, threatened by the Commission.
(g) The Underwriters shall have received on the Closing Date a
letter, dated the Closing Date, in form and substance satisfactory to the
Underwriters, from Ernst & Young LLP, to the effect that they reaffirm the
statements made in the letter furnished pursuant to paragraph (e) of this
Section, except that the specified date referred to shall be a date not
more than two business days prior to the Closing Date.
5. Covenants of the Company. In further consideration of the
------------------------
agreements of the Underwriters contained herein, the Company covenants as
follows:
(a) To furnish the Underwriters, without charge, a signed copy of
the Registration Statement (including exhibits thereto) and, during the
period mentioned in paragraph (c) below, as many copies of the Prospectus,
any documents incorporated by reference therein and any supplements and
amendments thereto or to the Registration Statement as the Underwriters may
reasonably request.
(b) Before amending or supplementing the Registration Statement
or the Prospectus with respect to the Offered Securities, to furnish to the
Underwriters a copy of each such proposed amendment or supplement and not
to file any such proposed amendment or supplement to which the Underwriters
reasonably object.
(c) If, during such period after the first date of the public
offering of the Offered Securities as in the written opinion of counsel for
the Underwriters the Prospectus is required by law to be delivered in
con-
8
<PAGE>
nection with sales by an Underwriter or dealer, any event shall occur as a
result of which it is necessary to amend or supplement the Prospectus in
order to make the statements therein not misleading in the light of the
circumstances when the Prospectus is delivered to a purchaser, or if it is
necessary to amend or supplement the Prospectus to comply with law,
forthwith to prepare and furnish, at its own expense, to the Underwriters
and to the dealers (whose names and addresses the Underwriters will furnish
to the Company) to which Offered Securities may have been sold by the
Underwriters and to any other dealer upon request, either amendments or
supplements to the Prospectus so that the statements in the Prospectus as
so amended or supplemented will not be misleading in the light of the
circumstances when the Prospectus is delivered to a purchaser, or so that
the Prospectus, as so amended or supplemented, will comply with law.
(d) To endeavor to qualify the Offered Securities for offer and
sale under the securities or Blue Sky laws of such jurisdictions as the
Underwriters shall reasonably request and to pay all expenses (including
reasonable fees and disbursements of counsel) in connection with such
qualification.
(e) To make generally available to the Company's security holders
and to the Underwriters as soon as practicable an earning statement
covering a 12-month period beginning on the first day of the first full
fiscal quarter after the date of this Agreement, which earning statement
shall satisfy the provisions of Section 11(a) of the Securities Act and the
rules and regulations of the Commission thereunder.
(f) During the period beginning on the date of this Agreement and
continuing to and including the Closing Date, not to offer, sell, contract
to sell or otherwise dispose of any debt securities of the Company
substantially similar to the Offered Securities (other than (i) the Offered
Securities and (ii) commercial paper issued in the ordinary course of
business), without the prior written consent of the Underwriters.
6. Indemnification and Contribution. The Company agrees to
--------------------------------
indemnify and hold harmless each Underwriter and each person, if any, who
controls such Underwriter within the meaning of either Section 15 of the
Securities Act or Section 20 of the Exchange Act from and against any and all
losses, claims, damages and liabilities caused by any untrue statement or
alleged untrue statement
9
<PAGE>
of a material fact contained in the Registration Statement (as amended if the
Company shall have furnished any amendments thereto), or the omission or alleged
omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading or caused by any untrue
statement of material fact contained in any preliminary prospectus or the
Prospectus (as amended or supplemented if the Company shall have furnished any
amendments or supplements thereto), or the omission or alleged omission to state
therein a material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading,
except insofar as such losses, claims, damages or liabilities are caused by any
such untrue statement or omission or alleged untrue statement or omission based
upon information relating to any Underwriter furnished to the Company in writing
by such Underwriter expressly for use therein; provided, however, that the
-------- -------
foregoing indemnity agreement with respect to any preliminary prospectus shall
not inure to the benefit of any Underwriter from whom the person asserting any
such losses, claims, damages or liabilities purchased Offered Securities, or any
person controlling such Underwriter, if a copy of the Prospectus (as then
amended or supplemented if the Company shall have furnished any amendments or
supplements thereto) was not sent or given by or on behalf of such Underwriter
to such person, if required by law so to have been delivered, at or prior to the
written confirmation of the sale of the Offered Securities to such person, and
if the Prospectus (as so amended or supplemented) would have cured the defect
giving rise to such losses, claims, damages or liabilities.
Each Underwriter agrees, severally and not jointly, to indemnify and
hold harmless the Company, its directors, its officers who sign the Registration
Statement and each person, if any, who controls the Company within the meaning
of either Section 15 of the Securities Act or Section 20 of the Exchange Act to
the same extent as the foregoing indemnity from the Company to each Underwriter,
but only with reference to information relating to such Underwriter furnished to
the Company by such Underwriter in writing expressly for use in the Registration
Statement, any preliminary prospectus, the Prospectus or any amendments or
supplements thereto.
In case any proceeding (including any governmental investigation)
shall be instituted involving any person in respect of which indemnity may be
sought pursuant to either of the two preceding paragraphs, such person (the
"indemnified party") shall promptly notify the person against whom such
indemnity may be sought (the "indemnifying party") in writing and the
indemnifying
11
<PAGE>
party, upon request of the indemnified party, shall retain counsel reasonably
satisfactory to the indemnified party to represent the indemnified party and any
others the indemnifying party may designate in such proceeding and shall pay the
reasonable fees and disbursements of such counsel related to such proceeding. In
any such proceeding, any indemnified party shall have the right to retain its
own counsel, but the fees and expenses of such counsel shall be at the expense
of such indemnified party unless (i) the indemnifying party and the indemnified
party shall have mutually agreed to the retention of such counsel or (ii) the
named parties to any such proceeding (including any impleaded parties) include
both the indemnifying party and the indemnified party and representation of both
parties by the same counsel would, in the written opinion of independent legal
counsel, be inappropriate due to actual or potential differing interests between
them. It is understood that the indemnifying party shall not, in connection with
any proceeding or related proceedings in the same jurisdiction, be liable for
the fees and expenses of more than one separate firm (in addition to any local
counsel) for all such indemnified parties and that all such fees and expenses
shall be reimbursed as they are incurred. Such firm shall be designated in
writing by Goldman, Sachs & Co. in the case of parties indemnified pursuant to
the second preceding paragraph, and by the Company, in the case of parties
indemnified pursuant to the first preceding paragraph. The indemnifying party
shall not be liable for any settlement of any proceeding effected without its
written consent, but if settled with such consent or if there be a final
judgment for the plaintiff, the indemnifying party agrees to indemnify the
indemnified party from and against any loss or liability by reason of such
settlement or judgment. No indemnifying party shall, without the prior written
consent of the indemnified party, effect any settlement of any pending or
threatened proceeding in respect of which any indemnified party is or could have
been a party and indemnity could have been sought hereunder by such indemnified
party, unless such settlement includes an unconditional release of such
indemnified party from all liability on claims that are the subject matter of
such proceeding.
If the indemnification provided for in the first or second paragraph
in this Section 6 is unavailable to an indemnified party or insufficient in
respect of any losses, claims, damages or liabilities referred to therein, then
each indemnifying party under such paragraph, in lieu of indemnifying such
indemnified party thereunder, shall contribute to the amount paid or payable by
such indemnified party as a result of such losses, claims, damages or
liabilities (i) in such proportion as is appropriate to reflect the relative
benefits received by the Company and the Underwriters from the offering of the
Offered Securities or (ii) if the allocation provided by clause (i) above is not
permitted by applicable law, in such proportion
11
<PAGE>
as is appropriate to reflect not only the relative benefits referred to in
clause (i) above but also the relative fault of the Company and of the
Underwriters in connection with the statements or omissions that resulted in
such losses, claims, damages or liabilities, as well as any other relevant
equitable considerations. The relative benefits received by the Company and the
Underwriters in connection with the offering of the Offered Securities shall be
deemed to be in the same respective proportions as the net proceeds from the
offering of such Offered Securities (before deducting expenses) received by the
Company and the total underwriting discounts and commissions received by the
Underwriters, in each case as set forth in the table on the cover of the
Prospectus Supplement, bear to the aggregate public offering price of the
Offered Securities. The relative fault of the Company and of the Underwriters
shall be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission or alleged omission
to state a material fact relates to information supplied by the Company or by
the Underwriters and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.
The Company and the Underwriters agree that it would not be just or
equitable if contribution pursuant to this Section 6 were determined by pro rata
allocation (even if the Underwriters were treated as one entity for such
purpose) or by any other method of allocation that does not take account of the
equitable considerations referred to in the immediately preceding paragraph.
The amount paid or payable by an indemnified party as a result of the losses,
claims, damages and liabilities referred to in the immediately preceding
paragraph shall be deemed to include, subject to the limitations set forth
above, any legal or other expenses reasonably incurred by such indemnified party
in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this Section 6, no Underwriter shall be
required to contribute any amount in excess of the amount by which the total
price at which the Offered Securities underwritten by it and distributed to the
public were offered to the public exceeds the amount of any damages that such
Underwriter has otherwise been required to pay by reason of such untrue or
allegedly untrue statement or omission or alleged omission. No person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The Underwriters' respective
obligations to contribute pursuant to this Section 6 are several in proportion
to the respective principal amount of Offered Securities purchased by each of
such Underwriters and not joint. The remedies provided for in this Section 6
are not
12
<PAGE>
exclusive and shall not limit any rights or remedies which may otherwise be
available to any indemnified party at law or in equity.
The indemnity and contribution provisions contained in this Section 6
and the representations and warranties of the Company contained herein shall
remain operative and in full force and effect regardless of (i) any termination
of this Agreement, (ii) any investigation made by or on behalf of any
Underwriter or any person controlling any Underwriter or by or on behalf of the
Company, its directors or officers or any person controlling the Company and
(iii) delivery of the Offered Securities to the Underwriters.
7. Termination. This Agreement shall be subject to termination in
-----------
the Underwriters' absolute discretion, by notice given to the Company, if (a)
after the execution and delivery of this Agreement and prior to the Closing Date
(i) trading generally shall have been suspended or materially limited on or by,
as the case may be, any of the New York Stock Exchange, the American Stock
Exchange or the National Association of Securities Dealers, Inc., (ii) trading
of any securities of the Company shall have been suspended on any exchange or in
any over-the-counter market, (iii) a general moratorium on commercial banking
activities in New York shall have been declared by either Federal or New York
State authorities, or (iv) there shall have occurred any outbreak or escalation
of hostilities or any change in financial markets or any calamity or crisis
that, in the judgment of the Underwriters, is material and adverse and (b) in
the case of any of the events specified in clauses (a)(i) through (iv), such
event, singly or together with any other such event, makes it, in the judgment
of the Underwriters, impracticable to market the Offered Securities on the terms
and in the manner contemplated in the Prospectus.
8. Defaulting Underwriters. If on the Closing Date any one or more
-----------------------
of the Underwriters shall fail or refuse to purchase Offered Securities that it
has or they have agreed to purchase on such date, and the aggregate amount of
Offered Securities which such defaulting Underwriter or Underwriters agreed but
failed or refused to purchase is not more than one-tenth of the aggregate amount
of the Offered Securities to be purchased on such date, the other Underwriters
shall be obligated severally in the proportions that the amount of Offered
Securities set forth opposite their respective names above bears to the
aggregate amount of Offered Securities set forth opposite the names of all such
non-defaulting Underwriters, or in such other proportions as the Underwriters
may specify, to purchase the Offered Securities which such defaulting
Underwriter or Underwriters agreed
13
<PAGE>
but failed or refused to purchase on such date; provided that in no event shall
--------
the amount of Offered Securities that any Underwriter has agreed to purchase
pursuant to this Agreement be increased pursuant to this Section 8 by an amount
in excess of one-ninth of such amount of Offered Securities without the written
consent of such Underwriter. If on the Closing Date any Underwriter or
Underwriters shall fail or refuse to purchase Offered Securities and the
aggregate amount of Offered Securities with respect to which such default occurs
is more than one-tenth of the aggregate amount of Offered Securities to be
purchased on such date, and arrangements satisfactory to the Underwriters and
the Company for the purchase of such Offered Securities are not made within 36
hours after such default, this Agreement shall terminate without liability on
the part of any non-defaulting Underwriter or the Company. In any such case
either the Underwriters or the Company shall have the right to postpone the
Closing Date but in no event for longer than seven days, in order that the
required changes, if any, in the Registration Statement and in the Prospectus or
in any other documents or arrangements may be effected. Any action taken under
this paragraph shall not relieve any defaulting Underwriter from liability in
respect of any default of such Underwriter under this Agreement.
If this Agreement shall be terminated by the Underwriters, or any of
them, because of any failure or refusal on the part of the Company to comply
with the terms or to fulfill any of the conditions of this Agreement, or if for
any reason the Company shall be unable to perform its obligations under this
Agreement, the Company will reimburse the Underwriters or such Underwriters as
have so terminated this Agreement with respect to themselves, severally, for all
out-of-pocket expenses (including the reasonable fees and disbursements of their
counsel) reasonably incurred by such Underwriters in connection with the Offered
Securities.
9. Miscellaneous. This Agreement may be signed in any number of
-------------
counterparts, each of which shall be an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument.
This Agreement shall be governed by and construed in accordance with
the internal laws of the State of New York.
10. Headings. The headings of the sections of this Agreement have
--------
been inserted for convenience of reference only and shall not be deemed a part
of this Agreement.
14
<PAGE>
Exhibit A
Opinion of George A. Vandeman,
General Counsel for the Company
The opinion of George A. Vandeman, General Counsel for the Company, to
be delivered pursuant to Section 4(b) of the Underwriting Agreement, shall be
substantially to the effect that:
(i) the Company has been duly incorporated and is validly
existing and in good standing under the laws of the State of Delaware, with
corporate power and authority to own, lease and operate its properties and
to conduct its business as described in the Registration Statement and the
Prospectus. Based solely on certificates from public officials, I confirm
that the Company is qualified to do business in the following states:
California North Carolina
Florida Ohio
Massachusetts Pennsylvania
Michigan Tennessee
Missouri Virginia
New Jersey Wisconsin
New York
(ii) based solely on certificates from public officials, I
confirm that Kirin-Amgen, Inc. has been duly incorporated and is validly
existing and in good standing under the laws of the State of Delaware, and,
based solely on the Certificate of Incorporation of Kirin-Amgen, Inc., has
the corporate power and authority to own, lease and operate its properties
and to conduct its business as described in the Registration Statement and
the Prospectus;
(iii) the Underwriting Agreement has been duly authorized,
executed and delivered by the Company;
A-1
<PAGE>
(iv) the execution and delivery by the Company of, and the
issuance and sale of the Offered Securities pursuant to, the Underwriting
Agreement (A) will not contravene (i) the Restated Certificate of
Incorporation, as amended or the Amended and Restated By-laws of the
Company or (ii) any agreement or other instrument identified as an exhibit
to the Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 1996; the Company's Quarterly Reports on Form 10-Q for the
quarters ended March 31, June 30 and September 30, 1997; or the Company's
Current Reports on Form 8-K dated February 18, 1997, March 14, 1997 and
April 8, 1997; and (B) to the best of my knowledge (i) will not contravene
any provision of applicable law, (ii) will not contravene any judgment,
order or decree of any governmental body, agency or court having
jurisdiction over the Company or Kirin-Amgen, Inc. or their respective
business or assets, and (iii) no consent, approval or authorization or
order of or qualification with any governmental body or agency is required
for the issuance and sale of the Offered Securities by the Company under
the Underwriting Agreement, except such as are specified and have been
obtained and as may be required by the securities or Blue Sky laws of the
various states in connection with the offer and sale of the Offered
Securities;
(v) to the best of my knowledge, there are no (A) legal or
governmental proceedings pending or threatened to which the Company is a
party or to which any of the properties of the Company is subject that are
required to be described in the Registration Statement or the Prospectus
and are not so described, or (B) contracts or other documents that are
required to be filed as exhibits to the Registration Statement that are not
filed as required; and
(vi) each document filed pursuant to the Exchange Act and
incorporated by reference in the Prospectus (except for financial
statements, schedules and other financial data included or incorporated
therein as to which I express no opinion) complied when so filed as to form
in all material respects with the Exchange Act and the applicable rules and
regulations of the Commission thereunder.
In addition, I have participated in conferences with officers and
other representatives of the Company, representatives of the independent public
accountants for the Company and representatives of the Underwriters, at which
the
A-2
<PAGE>
contents of the Registration Statement and the Prospectus and related matters
were discussed and, although I am not passing upon, and do not assume any
responsibility for, the accuracy, completeness or fairness of the statements
contained in the Registration Statement and the Prospectus and have not made any
independent check or verification thereof, during the course of such
participation (relying as to materiality to the extent I have deemed appropriate
upon the statements of officers and other representatives of the Company), no
facts came to my attention that caused me to believe that the Registration
Statement, at the time it became effective, contained an untrue statement of a
material fact or omitted to state a material fact required to be stated therein
or necessary to make the statements therein not misleading, or that the
Prospectus, as of its date and as of the date hereof, contained an untrue
statement of a material fact or omitted to state a material fact necessary to
make the statements therein, in light of the circumstances under which they were
made, not misleading; it being understood that I express no belief with respect
to the financial statements, schedules and other financial data included in the
Registration Statement or the Prospectus or incorporated therein by reference or
with respect to the Form T-1.
Counsel for the Company may limit his opinion to the laws of the
States of Delaware and California, and the federal laws of the United States.
A-3
<PAGE>
Exhibit B
Opinion of Latham & Watkins,
Special Counsel for the Company
The opinion of counsel to the Company, to be delivered pursuant to
Section 4(c) of the Underwriting Agreement, shall be substantially to the effect
that:
(i) the Indenture has been duly authorized, executed and delivered by
the Company and (assuming due authorization, execution and delivery by the
Trustee) is the legally valid and binding agreement of the Company,
enforceable against the Company in accordance with its terms;
(ii) the Offered Securities have been duly authorized and, when
executed and authenticated in accordance with the provisions of the
Indenture and delivered to and paid for by the Underwriters in accordance
with the terms of the Underwriting Agreement, will be entitled to the
benefits provided by the Indenture and will be a legally valid and binding
obligation of the Company, enforceable against the Company in accordance
with their terms;
(iii) the statements in the Prospectus Supplement under the caption
"Description of the Notes" and in the Basic Prospectus under the caption
"Description of Debt Securities" insofar as such statements constitute
summaries of the legal matters or documents referred to therein, are
accurate in all material respects; and
(iv) the Registration Statement and Prospectus (except for financial
statements, schedules and other financial data included or incorporated
herein as to which such counsel need not express any opinion), comply as to
form in all material respects with the Securities Act and the applicable
rules and regulations of the Commission thereunder.
Counsel for the Company may limit their opinion to the laws of the
States of Delaware, California and New York and the federal laws of the United
States. Such counsel's opinion shall be subject to the following exceptions,
B-1
<PAGE>
limitations and qualifications: (A) the effect of bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance or other similar laws now or
hereafter in effect relating to or affecting the rights and remedies of
creditors; (B) the effect of general principles of equity, whether enforcement
is considered in a proceeding in equity or law, and the discretion of the court
before which any proceeding therefor may be brought; (C) the unenforceability
under certain circumstances under law or court decisions of provisions providing
for the indemnification of or contribution to a party with respect to a
liability where such indemnification or contribution is contrary to public
policy; (D) we express no opinion concerning the enforceability of the waiver of
rights or defenses contained in the Indenture; and (E) we express no opinion
with respect to whether the acceleration of the Offered Securities may affect
the collectibility of that portion of the stated principal amount thereof which
might be determined to constitute unearned interest thereon. With respect to
paragraph (iv) above, such counsel may state that such counsel's opinion assumes
that the statements made and incorporated by reference in the Prospectus and
Registration Statement are correct and complete.
B-2
<PAGE>
Exhibit C
Opinion of Skadden, Arps, Slate, Meagher & Flom LLP,
Counsel for the Underwriters
The opinion of Skadden, Arps, Slate, Meagher & Flom LLP, counsel for
the Underwriters, to be delivered pursuant to Section 4(d) of the Underwriting
Agreement, shall be substantially to the effect that:
(i) the Underwriting Agreement has been duly authorized, executed and
delivered by the Company;
(ii) the Indenture has been qualified under the Trust Indenture Act of
1939, as amended, and has been duly authorized, executed and delivered by
the Company and is a valid and binding agreement of the Company,
enforceable in accordance with its terms except to the extent that
enforcement thereof may be limited by (i) bankruptcy, insolvency,
reorganization, moratorium or other similar laws now or hereafter in effect
relating to creditors' rights generally and (ii) general principles of
equity (regardless of whether enforceability is considered in a proceeding
at law or in equity);
(iii) the issuance and sale of the Offered Securities have been duly
authorized by the Company, and the Offered Securities, when executed and
authenticated in accordance with the provisions of the Indenture and
delivered to and paid for by the Underwriters in accordance with the terms
of the Underwriting Agreement, will be entitled to the benefits of the
Indenture and will be valid and binding obligations of the Company
enforceable in accordance with their terms except to the extent that
enforcement thereof may be limited by (i) bankruptcy, insolvency,
reorganization, moratorium or other similar laws now or hereafter in effect
relating to creditors' rights generally and (ii) general principles of
equity (regardless of whether enforceability is considered in a proceeding
at law or in equity);/*/
- ---------------------
/*/ Assumes U.S. dollar denominated Offered Securities.
C-1
<PAGE>
(iv) The Registration Statement, as of its effective date, and the
Prospectus, as of the date of the Prospectus Supplement, appeared on their
face to be appropriately responsive in all material respects to the
requirements of the Act and the Rules and Regulations, except that in each
case (A) we express no opinion as to (i) the financial statements,
schedules and other financial data included or incorporated by reference
therein or excluded therefrom, (ii) the documents incorporated by reference
therein or (iii) the exhibits to the Registration Statement, including the
Form T-1, and (B) we do not assume any responsibility for the accuracy,
completeness or fairness of the statements contained in the Registration
Statement and the Prospectus.
In addition, we have participated in conferences with officers and
representatives of the Company, counsel for the Company, representatives of the
independent accountants of the Company and you at which the contents of the
Registration Statement and the Prospectus and related matters were discussed
and, although we are not passing upon, and do not assume any responsibility for,
the accuracy, completeness or fairness of the statements contained in the
Registration Statement or the Prospectus and have made no independent check or
verification thereof, on the basis of the foregoing, no facts have come to our
attention that have led us to believe that the Registration Statement, at the
time it became effective, contained an untrue statement of a material fact or
omitted to state any material fact required to be stated therein or necessary to
make the statements therein not misleading or that the Prospectus, as of the
date of the Prospectus Supplement and as of the date hereof, contained or
contains an untrue statement of a material fact or omitted or omits to state a
material fact necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading, except that we express
no opinion or belief with respect to (i) the financial statements, schedules and
other financial data included therein or excluded therefrom or (ii) the exhibits
to the Registration Statement, including the Form T-1.
C-2
<PAGE>
EXHIBIT 4.1
OFFICER'S CERTIFICATE
OF
AMGEN INC.
Pursuant to Sections 2.1 and 2.3 of the Indenture, dated as of January
1, 1992, as supplemented by a First Supplemental Indenture, dated as of February
26, 1997 (as so supplemented, the "Indenture") each between Amgen Inc., a
Delaware corporation (the "Company"), and Citibank, N.A., as trustee, the
undersigned officer of the Company hereby certifies as follows in connection
with the issuance of the Company's 6.50% Notes due December 1, 2007, under the
Indenture:
(i) the Notes shall constitute a series of Securities having the
title "6.50% Notes due December 1, 2007" (referred to herein as the "Notes");
(ii) the form of the Notes is attached hereto as Exhibit A;
(iii) the Notes, which may be authenticated and delivered under the
Indenture, shall be limited to $100,000,000 aggregate principal amount (except
for Notes authenticated and delivered upon registration of transfer of, in
exchange for, or in lieu of, other Notes pursuant to Section 2.8, 2.9, 2.11, 8.5
or 12.3 of the Indenture);
(iv) the Notes shall be issued as Registered Global Securities only,
without coupons, and beneficial interests in the Notes may be acquired, or
subsequently transferred, only in denominations of $1,000 and any integral
multiple thereof;
(v) the principal amount of the Notes shall be payable on December
1, 2007;
(vi) interest on the Notes shall accrue at a fixed rate of 6.50% per
annum; the Notes will bear interest from December 1, 2007, and such interest
will be payable semi-annually on June 1 and December 1 of each year, commencing
on June 1, 1998 (each, an "Interest Payment Date"); the record date with respect
to the Notes shall be the 15th day immediately preceding such Interest Payment
Date, whether or not a Business Day; and interest on the Notes will be
calculated on the basis of a 360-day year of twelve 30-day months;
(vii) principal and interest payable with respect to the Notes shall
be payable by Citibank, N.A., as paying agent;
(viii) the Notes are subject to redemption in whole or in part, at the
option of the Company at any time, at a redemption price equal to the greater of
(i) 100% of the principal amount to be redeemed or (ii) the sum of the present
values of the Remaining Scheduled Payments (as defined in the Notes) on the
redemption date
<PAGE>
discounted to maturity on a semiannual basis (assuming a 360-day year consisting
of twelve 30-day months) at the Treasury Yield (as defined in the Notes) plus 15
basis points, plus in each case accrued interest to the date of redemption;
(ix) the Notes are not subject to any sinking fund;
(x) Section 3.8 of the Indenture, "Limitation on Indebtedness of
Subsidiaries" shall not apply to the Notes; and
(xi) the Notes shall be issued in the form of a Registered Global
Security, the trustee for such Notes shall be Citibank, N.A. and the Depositary
for such Notes shall be The Depository Trust Company.
The undersigned further certifies, having read the Indenture and
certain other corporate documents and records, and having made such examination
or investigation as I have deemed necessary to enable me to express an informed
opinion, that all conditions precedent to the authentication and delivery of the
Notes have been complied with, and that the Notes delivered to the Trustee for
authentication have been duly executed and conform to the terms set forth herein
and in the Indenture.
<PAGE>
Unless otherwise indicated, capitalized terms used herein that are not
otherwise defined shall have the meanings ascribed thereto in the Indenture.
IN WITNESS WHEREOF, the undersigned has executed this Officer's
Certificate as of this 5th day of December, 1997.
/s/ Robert S. Attiyeh
-----------------------------------------
Robert S. Attiyeh
Senior Vice President,
Finance and Corporate Development, and
Chief Financial Officer
<PAGE>
EXHIBIT A
REGISTERED PRINCIPAL AMOUNT
NO. R-1 $100,000,000
CUSIP NO. 03116 2AB 6
AMGEN INC.
6.50% NOTES DUE DECEMBER 1, 2007
UNLESS THIS NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE
DEPOSITORY TRUST COMPANY ("DTC"), 55 WATER STREET, NEW YORK, NEW YORK TO THE
COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND SUCH
NOTE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO., OR SUCH OTHER NAME AS IS
REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO
CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED
REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR
OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER
HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.
UNLESS AND UNTIL THIS NOTE IS EXCHANGED IN WHOLE OR IN PART FOR
SECURITIES IN DEFINITIVE REGISTERED FORM, THIS NOTE MAY NOT BE TRANSFERRED
EXCEPT AS A WHOLE BY DTC TO THE NOMINEE OF DTC OR BY A NOMINEE OF DTC TO DTC OR
ANOTHER NOMINEE OF DTC OR BY DTC OR ANY SUCH NOMINEE TO A SUCCESSOR OF DTC OR A
NOMINEE OF SUCH SUCCESSOR.
AMGEN INC., a Delaware corporation (the "Company," which term shall
include any successor under the Indenture hereinafter referred to), for value
received, hereby promises to pay to CEDE & CO., or registered assigns, the
principal sum of One Hundred Million Dollars ($100,000,000) on December 1, 2007,
and to pay interest thereon at the rate of 6.50% per annum, until the entire
principal amount hereof is paid or duly provided for. This Note is one of a
duly authorized series issued by the Company and designated as the "6.50% Notes
due December 1, 2007" (referred to herein as the "Notes").
Unless otherwise indicated, capitalized terms used herein that are not
otherwise defined shall have the meanings ascribed thereto in the Indenture (as
defined below).
1. Definitions.
"Comparable Treasury Issue" means the United States Treasury security
selected by an Independent Investment Banker as having a maturity comparable to
the remaining terms of the Notes. If no such security exists, a security that
would be utilized, at the time of selection and in accordance with customary
financial practice, in pricing new issues of corporate debt securities of
comparable maturity to the remaining term of the Notes will be used.
"Independent Investment Banker" means Goldman, Sachs & Co. or Bear, Stearns &
Co. Inc. or, if either firm is unwilling or unable to select the Comparable
Treasury Issue, an independent investment banking institution of national
standing appointed by the Trustee (as defined herein).
<PAGE>
"Comparable Treasury Price" means, with respect to any redemption
date, (i) the average of the bid and asked prices for the Comparable Treasury
Issue (expressed in each case as a percentage of its principal amount) on the
third business day preceding such redemption date, as set forth in the daily
statistical release (or any successor release) published by the Federal Reserve
Bank of New York and designated "Composite 3:30 p.m. Quotations for U.S.
Government Securities" or (ii) if such release (or any successor release) is not
published or does not contain such prices on such business day, the average of
the Reference Treasury Dealer Quotations for such redemption date. "Reference
Treasury Dealer Quotations" means, with respect to each Reference Treasury
Dealer and any redemption date, the average of the bid and asked prices for the
Comparable Treasury Issue (expressed in each case as a percentage of its
principal amount) quoted in writing to the Trustee by such Reference Treasury
Dealer at 5:00 p.m. on the third business day preceding such redemption date.
"Reference Treasury Dealer" means each of Goldman, Sachs & Co. and
Bear, Stearns & Co. Inc., and their respective successors; provided, however,
that if any of the foregoing shall cease to be a primary U.S. Government
securities dealer in New York City (a "Primary Treasury Dealer"), the Company
shall substitute therefor another Primary Treasury Dealer.
"Remaining Scheduled Payments" means, with respect to any Note, the
remaining scheduled payments of the principal thereof to be redeemed and
interest thereon that would be due after the related redemption date but for
such redemption; provided, however, that, if such redemption date is not an
interest payment date with respect to such Note, the amount of the next
succeeding scheduled interest payment thereon will be reduced by the amount of
interest accrued thereon to such redemption date.
"Treasury Yield" means, with respect to any redemption date, the rate
per annum equal to the semiannual equivalent yield to maturity of the Comparable
Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as
a percentage of its principal amount) equal to the Comparable Treasury Price for
such redemption date.
2. Interest.
The Company will pay interest semiannually on June 1 and December 1 of
each year (each an "Interest Payment Date"), commencing on June 1, 1998.
Interest on the Notes will accrue from the most recent date to which interest
has been paid, unless the date hereof is a date to which interest has been paid,
in which case from the date of the Note, or, if no interest has been paid, from
December 1, 1997. Notwithstanding the foregoing, when there is no existing
default in the payment of interest on the Notes, if the date hereof is after a
record date, as that term is defined below, and before the next succeeding
Interest Payment Date, this Note shall bear interest from such Interest Payment
Date; provided, however, that if the Company shall default in the payment of
interest due on such Interest Payment Date, then this Note shall bear interest
from the next preceding Interest Payment Date to which interest has been paid,
or, if no interest has been paid on the Notes, from December 1, 1997. Interest
will be computed on the basis of a 360-day year of twelve 30-day months.
2
<PAGE>
3. Method of Payment.
The Company will pay interest on the Notes (except defaulted interest)
to the persons who are registered Holders of Notes at the close of business on
the 15th day immediately preceding such Interest Payment Date whether or not a
Business Day (a "record date"). Holders must surrender Notes to the paying
agent prior to collecting principal payments. The Company will pay principal
and interest in money of the United States that at the time of payment is legal
tender for payment of public and private debts. However, the Company may pay
principal and any interest by its check payable in such money. It may mail an
interest check to a Holder's registered address.
4. Paying Agent and Registrar.
Initially, the Trustee will act as paying agent and registrar. The
Company may change any paying agent, registrar or co-registrar without notice.
The Company or any of its subsidiaries may, subject to certain exceptions, act
as paying agent, registrar or co-registrar.
5. Indenture.
The Company issued the Notes under an Indenture, dated as of January
1, 1992, as supplemented by a First Supplemental Indenture, dated as of February
26, 1997 (as so supplemented, and including the Officer's Certificate dated
December 5, 1997 (the "Officer's Certificate") establishing the form and terms
of the Notes, the "Indenture"), each between the Company and Citibank, N.A., as
trustee (the "Trustee"). The terms of the Notes include those stated in the
Indenture and those made part of the Indenture by reference to the Trust
Indenture Act of 1939 (15 U.S. Code (S)(S) 77aaa-77bbbb) as in effect on the
date of the Indenture. The Notes are subject to all such terms and Holders are
referred to the Indenture and such Act for a statement of them.
6. Redemption at the Option of the Company.
The Notes will be redeemable as a whole or in part, at the option of
the Company at any time, at a redemption price equal to the greater of (i) 100%
of the principal amount to be redeemed or (ii) the sum of the present values of
the Remaining Scheduled Payments on the redemption date discounted to maturity
on a semiannual basis (assuming a 360-day year consisting of twelve 30-day
months) at the Treasury Yield plus 15 basis points, plus in each case accrued
interest to the date of redemption.
Holders of Notes to be redeemed will receive notice thereof by first-
class mail at least 30 and not more than 60 days prior to the date fixed for
redemption.
Unless the Company defaults in payment of the redemption price, on and
after the redemption date interest will cease to accrue on the Notes or portions
thereof called for redemption.
3
<PAGE>
7. Denominations, Transfer, Exchange.
The Notes are in registered form only. The registrar may require a
Holder, among other things, to furnish appropriate endorsements and transfer
documents and to pay any taxes and fees required by law or permitted by the
Indenture.
8. Persons Deemed Owners.
The Holder of a Note may be treated as the owner of it for all
purposes.
9. Unclaimed Money.
If money for the payment of principal or interest remains unclaimed
for two years, the Trustee or any paying agent will pay the money back to the
Company at its written request. After that, Holders entitled to the money must
look to the Company for payment unless an abandoned or unclaimed property law
designates another person, and all liability of the Trustee or any such paying
agent with respect to such money shall cease.
10. Discharge Prior to Maturity.
Subject to certain conditions, if the Company deposits with the
Trustee money or U.S. Government Obligations sufficient to pay principal of and
accrued interest on the Notes to maturity, the Company will be discharged (to
the extent provided in the Indenture) from the Indenture and the Notes.
11. Amendment, Supplement, Waiver.
Subject to certain exceptions requiring the consent of the Holders of
each of the affected Securities, at such time as the Notes are the only
Securities then outstanding under the Indenture, the Indenture or the Notes may
be amended or supplemented with the consent of the Holders of not less than a
majority in principal amount of the Notes then outstanding affected by such
amendment or supplement. Any past default or compliance with any provision as
to the Notes may be waived with the consent of the Holders of a majority in
principal amount of the Notes then outstanding. Without the consent of any
Holder, the Company and the Trustee may amend or supplement the Indenture or the
Notes to, among other things, cure any ambiguity, defect or inconsistency or to
make any change that does not materially adversely affect the rights of any
Holder.
12. Restrictive Covenants.
The Notes are general unsecured obligations of the Company limited to
the aggregate principal amount of $100,000,000. The Indenture does not limit
the Company from incurring unsecured Indebtedness other than the aggregate
principal amount of indebtedness to be issued pursuant to the Officer's
Certificate. It does limit the ability of the Company and its subsidiaries to
grant certain security interests in their property without equally and ratably
securing the Notes and to engage in certain sale and leaseback transactions,
subject to certain important exceptions
4
<PAGE>
described therein. Once a year the Company must report to the Trustee with
respect to its compliance with such limitations.
13. Successor Corporation.
When a successor corporation assumes all the obligations of its
predecessor under the Notes and the Indenture, the predecessor corporation will
be released from those obligations.
14. Defaults and Remedies.
An Event of Default is: default for 30 days in payment of interest on
any of the Notes; default in payment of principal of any of the Notes due and
payable at maturity or otherwise; failure by the Company for 90 days after
written notice to it to comply with any of its other agreements in the Indenture
or in the Notes; failure by the Company to make any payment at maturity in
respect of Indebtedness in an amount in excess of $10,000,000 and continuance of
such failure for a period of 30 days after notice to the Company by the Trustee
or to the Company and the Trustee by Holders of not less than 25% in aggregate
principal amount of the Securities issued under the Indenture (treated as one
class) then outstanding; the happening of an event of default under other
Indebtedness of the Company which default results in the acceleration of
Indebtedness in an amount in excess of $10,000,000, unless cured or waived in
accordance with the provisions of the applicable instrument, or discharged
within 30 days after notice to the Company by the Trustee or to the Company and
the Trustee by Holders of not less than 25% in aggregate principal amount of the
Securities issued under the Indenture (treated as one class) then outstanding;
and certain events of bankruptcy or insolvency. If an Event of Default occurs
and is continuing (other than an Event of Default relating to certain events of
bankruptcy or insolvency and certain Events of Default relating to all
outstanding Securities issued under the Indenture), the Trustee or the Holders
of not less than 25% in aggregate principal amount of the Notes then outstanding
may declare all the Notes to be due and payable immediately in accordance with
Section 5.1 of the Indenture. Holders may not enforce the Indenture or the
Notes except as provided in the Indenture. The Trustee may require security and
indemnity satisfactory to it before it enforces the Indenture or the Notes.
Subject to certain limitations, Holders of a majority in aggregate principal
amount of all of the Securities (treated as one class) then outstanding may
direct the Trustee in its exercise of any trust or power. The Trustee may
withhold from Holders notice of any continuing default (except a default in
payment of principal or interest) if it determines that withholding notice is in
their interests.
15. Trustee Dealings with Company.
Citibank, N.A., the Trustee under the Indenture, in its individual or
any other capacity, may make loans to, accept deposits from, and perform
services for the Company, and may otherwise deal with the Company, as if it were
not the Trustee.
16. No Recourse Against Others.
A past, present or future director, officer, employee, stockholder or
incorporator, as such, of the Company or successor corporation shall not have
any liability for any obligations
5
<PAGE>
of the Company under the Notes or the Indenture or for any claim based on, in
respect of, or by reason of such obligations or their creation. Each Holder by
accepting a Note waives and releases all such liability. The waiver and release
are part of the consideration for the issue of the Notes.
17. Authentication.
This Note shall not be valid until the Trustee signs the certificate
of authentication at the end of this Note.
18. Copies of the Indenture.
The Company will furnish to any Holder upon written request and
without charge a copy of the Indenture. Requests may be made to:
Amgen Inc.
1840 DeHavilland Drive
Thousand Oaks, California 91320
Attention: General Counsel
19. Abbreviations and Defined Terms.
Customary abbreviations may be used in the name of a Holder of a Note
or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by
the entireties), JT TEN (= joint tenants with right of survivorship and not as
tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform Gifts to Minors
Act).
20. CUSIP Numbers.
Pursuant to a recommendation promulgated by the Committee on Uniform
Security Identification Procedures, the Company will cause CUSIP numbers to be
printed on the Notes as a convenience to the Holders of the Notes. No
representation is made as to the accuracy of such numbers as printed on the
Notes and reliance may be placed only on the other identification numbers
printed hereon.
[Signature Page To Follow]
6
<PAGE>
IN WITNESS WHEREOF, the Company has caused this instrument to be duly
executed under its corporate seal this 5th day of December, 1997.
By:______________________________________
Robert S. Attiyeh
Senior Vice President, Finance and
Corporate Development, and Chief
Financial Officer
(SEAL)
TRUSTEE'S CERTIFICATE OF AUTHENTICATION:
This is one of the Securities referred to in the within-mentioned
Indenture.
Citibank, N.A.,
as Trustee
By: _________________________
Authorized Signatory
S-1
<PAGE>
ASSIGNMENT FORM
FOR VALUE RECEIVED, THE UNDERSIGNED HEREBY
SELLS, ASSIGNS AND TRANSFERS TO
PLEASE INSERT SOCIAL
SECURITY OR OTHER IDENTIFYING
NUMBER OF ASSIGNEE
................................................................................
................................................................................
(Please Print or Typewrite Name and Address
including Zip Code of Assignee)
................................................................................
the within Note of __________________________________ and ______________ hereby
does irrevocably constitute and appoint
................................................................................
Attorney to transfer said Note on the books of the within-named Company with
full power of substitution in the premises.
Dated: ................. .........................................
.........................................
NOTICE: The signature to this assignment must correspond with the name as it
appears on the first page of the within Note in every particular, without
alteration or enlargement or any change whatever.
Signature Guaranteed:
__________________________________
Authorized Signature
Signature guarantee should be made
by a guarantor institution
participating in the Securities
Transfer Agents Medallion Program
or in such guarantee program
acceptable to the Trustee.
A-1
<PAGE>
EXHIBIT 4.2
REGISTERED PRINCIPAL AMOUNT
NO. R-1 $100,000,000
CUSIP NO. 03116 2AB 6
AMGEN INC.
6.50% NOTES DUE DECEMBER 1, 2007
UNLESS THIS NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE
DEPOSITORY TRUST COMPANY ("DTC"), 55 WATER STREET, NEW YORK, NEW YORK TO THE
COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND SUCH
NOTE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO., OR SUCH OTHER NAME AS IS
REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO
CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED
REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR
OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER
HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.
UNLESS AND UNTIL THIS NOTE IS EXCHANGED IN WHOLE OR IN PART FOR
SECURITIES IN DEFINITIVE REGISTERED FORM, THIS NOTE MAY NOT BE TRANSFERRED
EXCEPT AS A WHOLE BY DTC TO THE NOMINEE OF DTC OR BY A NOMINEE OF DTC TO DTC OR
ANOTHER NOMINEE OF DTC OR BY DTC OR ANY SUCH NOMINEE TO A SUCCESSOR OF DTC OR A
NOMINEE OF SUCH SUCCESSOR.
AMGEN INC., a Delaware corporation (the "Company," which term shall
include any successor under the Indenture hereinafter referred to), for value
received, hereby promises to pay to CEDE & CO., or registered assigns, the
principal sum of One Hundred Million Dollars ($100,000,000) on December 1, 2007,
and to pay interest thereon at the rate of 6.50% per annum, until the entire
principal amount hereof is paid or duly provided for. This Note is one of a
duly authorized series issued by the Company and designated as the "6.50% Notes
due December 1, 2007" (referred to herein as the "Notes").
Unless otherwise indicated, capitalized terms used herein that are not
otherwise defined shall have the meanings ascribed thereto in the Indenture (as
defined below).
1. Definitions.
"Comparable Treasury Issue" means the United States Treasury security
selected by an Independent Investment Banker as having a maturity comparable to
the remaining terms of the Notes. If no such security exists, a security that
would be utilized, at the time of selection and in accordance with customary
financial practice, in pricing new issues of corporate debt securities of
comparable maturity to the remaining term of the Notes will be used.
"Independent Investment Banker" means Goldman, Sachs & Co. or Bear, Stearns &
Co. Inc. or, if either firm is unwilling or unable to select the Comparable
Treasury Issue, an independent investment banking institution of national
standing appointed by the Trustee (as defined herein).
<PAGE>
"Comparable Treasury Price" means, with respect to any redemption
date, (i) the average of the bid and asked prices for the Comparable Treasury
Issue (expressed in each case as a percentage of its principal amount) on the
third business day preceding such redemption date, as set forth in the daily
statistical release (or any successor release) published by the Federal Reserve
Bank of New York and designated "Composite 3:30 p.m. Quotations for U.S.
Government Securities" or (ii) if such release (or any successor release) is not
published or does not contain such prices on such business day, the average of
the Reference Treasury Dealer Quotations for such redemption date. "Reference
Treasury Dealer Quotations" means, with respect to each Reference Treasury
Dealer and any redemption date, the average of the bid and asked prices for the
Comparable Treasury Issue (expressed in each case as a percentage of its
principal amount) quoted in writing to the Trustee by such Reference Treasury
Dealer at 5:00 p.m. on the third business day preceding such redemption date.
"Reference Treasury Dealer" means each of Goldman, Sachs & Co. and
Bear, Stearns & Co. Inc., and their respective successors; provided, however,
that if any of the foregoing shall cease to be a primary U.S. Government
securities dealer in New York City (a "Primary Treasury Dealer"), the Company
shall substitute therefor another Primary Treasury Dealer.
"Remaining Scheduled Payments" means, with respect to any Note, the
remaining scheduled payments of the principal thereof to be redeemed and
interest thereon that would be due after the related redemption date but for
such redemption; provided, however, that, if such redemption date is not an
interest payment date with respect to such Note, the amount of the next
succeeding scheduled interest payment thereon will be reduced by the amount of
interest accrued thereon to such redemption date.
"Treasury Yield" means, with respect to any redemption date, the rate
per annum equal to the semiannual equivalent yield to maturity of the Comparable
Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as
a percentage of its principal amount) equal to the Comparable Treasury Price for
such redemption date.
2. Interest.
The Company will pay interest semiannually on June 1 and December 1 of
each year (each an "Interest Payment Date"), commencing on June 1, 1998.
Interest on the Notes will accrue from the most recent date to which interest
has been paid, unless the date hereof is a date to which interest has been paid,
in which case from the date of the Note, or, if no interest has been paid, from
December 1, 1997. Notwithstanding the foregoing, when there is no existing
default in the payment of interest on the Notes, if the date hereof is after a
record date, as that term is defined below, and before the next succeeding
Interest Payment Date, this Note shall bear interest from such Interest Payment
Date; provided, however, that if the Company shall default in the payment of
interest due on such Interest Payment Date, then this Note shall bear interest
from the next preceding Interest Payment Date to which interest has been paid,
or, if no interest has been paid on the Notes, from December 1, 1997. Interest
will be computed on the basis of a 360-day year of twelve 30-day months.
2
<PAGE>
3. Method of Payment.
The Company will pay interest on the Notes (except defaulted interest)
to the persons who are registered Holders of Notes at the close of business on
the 15th day immediately preceding such Interest Payment Date whether or not a
Business Day (a "record date"). Holders must surrender Notes to the paying
agent prior to collecting principal payments. The Company will pay principal
and interest in money of the United States that at the time of payment is legal
tender for payment of public and private debts. However, the Company may pay
principal and any interest by its check payable in such money. It may mail an
interest check to a Holder's registered address.
4. Paying Agent and Registrar.
Initially, the Trustee will act as paying agent and registrar. The
Company may change any paying agent, registrar or co-registrar without notice.
The Company or any of its subsidiaries may, subject to certain exceptions, act
as paying agent, registrar or co-registrar.
5. Indenture.
The Company issued the Notes under an Indenture, dated as of January
1, 1992, as supplemented by a First Supplemental Indenture, dated as of February
26, 1997 (as so supplemented, and including the Officer's Certificate dated
December 5, 1997 (the "Officer's Certificate") establishing the form and terms
of the Notes, the "Indenture"), each between the Company and Citibank, N.A., as
trustee (the "Trustee"). The terms of the Notes include those stated in the
Indenture and those made part of the Indenture by reference to the Trust
Indenture Act of 1939 (15 U.S. Code (S)(S) 77aaa-77bbbb) as in effect on the
date of the Indenture. The Notes are subject to all such terms and Holders are
referred to the Indenture and such Act for a statement of them.
6. Redemption at the Option of the Company.
The Notes will be redeemable as a whole or in part, at the option of
the Company at any time, at a redemption price equal to the greater of (i) 100%
of the principal amount to be redeemed or (ii) the sum of the present values of
the Remaining Scheduled Payments on the redemption date discounted to maturity
on a semiannual basis (assuming a 360-day year consisting of twelve 30-day
months) at the Treasury Yield plus 15 basis points, plus in each case accrued
interest to the date of redemption.
Holders of Notes to be redeemed will receive notice thereof by first-
class mail at least 30 and not more than 60 days prior to the date fixed for
redemption.
Unless the Company defaults in payment of the redemption price, on and
after the redemption date interest will cease to accrue on the Notes or portions
thereof called for redemption.
3
<PAGE>
7. Denominations, Transfer, Exchange.
The Notes are in registered form only. The registrar may require a
Holder, among other things, to furnish appropriate endorsements and transfer
documents and to pay any taxes and fees required by law or permitted by the
Indenture.
8. Persons Deemed Owners.
The Holder of a Note may be treated as the owner of it for all
purposes.
9. Unclaimed Money.
If money for the payment of principal or interest remains unclaimed
for two years, the Trustee or any paying agent will pay the money back to the
Company at its written request. After that, Holders entitled to the money must
look to the Company for payment unless an abandoned or unclaimed property law
designates another person, and all liability of the Trustee or any such paying
agent with respect to such money shall cease.
10. Discharge Prior to Maturity.
Subject to certain conditions, if the Company deposits with the
Trustee money or U.S. Government Obligations sufficient to pay principal of and
accrued interest on the Notes to maturity, the Company will be discharged (to
the extent provided in the Indenture) from the Indenture and the Notes.
11. Amendment, Supplement, Waiver.
Subject to certain exceptions requiring the consent of the Holders of
each of the affected Securities, at such time as the Notes are the only
Securities then outstanding under the Indenture, the Indenture or the Notes may
be amended or supplemented with the consent of the Holders of not less than a
majority in principal amount of the Notes then outstanding affected by such
amendment or supplement. Any past default or compliance with any provision as
to the Notes may be waived with the consent of the Holders of a majority in
principal amount of the Notes then outstanding. Without the consent of any
Holder, the Company and the Trustee may amend or supplement the Indenture or the
Notes to, among other things, cure any ambiguity, defect or inconsistency or to
make any change that does not materially adversely affect the rights of any
Holder.
12. Restrictive Covenants.
The Notes are general unsecured obligations of the Company limited to
the aggregate principal amount of $100,000,000. The Indenture does not limit
the Company from incurring unsecured Indebtedness other than the aggregate
principal amount of indebtedness to be issued pursuant to the Officer's
Certificate. It does limit the ability of the Company and its subsidiaries to
grant certain security interests in their property without equally and ratably
securing the Notes and to engage in certain sale and leaseback transactions,
subject to certain important exceptions
4
<PAGE>
described therein. Once a year the Company must report to the Trustee with
respect to its compliance with such limitations.
13. Successor Corporation.
When a successor corporation assumes all the obligations of its
predecessor under the Notes and the Indenture, the predecessor corporation will
be released from those obligations.
14. Defaults and Remedies.
An Event of Default is: default for 30 days in payment of interest on
any of the Notes; default in payment of principal of any of the Notes due and
payable at maturity or otherwise; failure by the Company for 90 days after
written notice to it to comply with any of its other agreements in the Indenture
or in the Notes; failure by the Company to make any payment at maturity in
respect of Indebtedness in an amount in excess of $10,000,000 and continuance of
such failure for a period of 30 days after notice to the Company by the Trustee
or to the Company and the Trustee by Holders of not less than 25% in aggregate
principal amount of the Securities issued under the Indenture (treated as one
class) then outstanding; the happening of an event of default under other
Indebtedness of the Company which default results in the acceleration of
Indebtedness in an amount in excess of $10,000,000, unless cured or waived in
accordance with the provisions of the applicable instrument, or discharged
within 30 days after notice to the Company by the Trustee or to the Company and
the Trustee by Holders of not less than 25% in aggregate principal amount of the
Securities issued under the Indenture (treated as one class) then outstanding;
and certain events of bankruptcy or insolvency. If an Event of Default occurs
and is continuing (other than an Event of Default relating to certain events of
bankruptcy or insolvency and certain Events of Default relating to all
outstanding Securities issued under the Indenture), the Trustee or the Holders
of not less than 25% in aggregate principal amount of the Notes then outstanding
may declare all the Notes to be due and payable immediately in accordance with
Section 5.1 of the Indenture. Holders may not enforce the Indenture or the
Notes except as provided in the Indenture. The Trustee may require security and
indemnity satisfactory to it before it enforces the Indenture or the Notes.
Subject to certain limitations, Holders of a majority in aggregate principal
amount of all of the Securities (treated as one class) then outstanding may
direct the Trustee in its exercise of any trust or power. The Trustee may
withhold from Holders notice of any continuing default (except a default in
payment of principal or interest) if it determines that withholding notice is in
their interests.
15. Trustee Dealings with Company.
Citibank, N.A., the Trustee under the Indenture, in its individual or
any other capacity, may make loans to, accept deposits from, and perform
services for the Company, and may otherwise deal with the Company, as if it were
not the Trustee.
16. No Recourse Against Others.
A past, present or future director, officer, employee, stockholder or
incorporator, as such, of the Company or successor corporation shall not have
any liability for any obligations
5
<PAGE>
of the Company under the Notes or the Indenture or for any claim based on, in
respect of, or by reason of such obligations or their creation. Each Holder by
accepting a Note waives and releases all such liability. The waiver and release
are part of the consideration for the issue of the Notes.
17. Authentication.
This Note shall not be valid until the Trustee signs the certificate
of authentication at the end of this Note.
18. Copies of the Indenture.
The Company will furnish to any Holder upon written request and
without charge a copy of the Indenture. Requests may be made to:
Amgen Inc.
1840 DeHavilland Drive
Thousand Oaks, California 91320
Attention: General Counsel
19. Abbreviations and Defined Terms.
Customary abbreviations may be used in the name of a Holder of a Note
or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by
the entireties), JT TEN (= joint tenants with right of survivorship and not as
tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform Gifts to Minors
Act).
20. CUSIP Numbers.
Pursuant to a recommendation promulgated by the Committee on Uniform
Security Identification Procedures, the Company will cause CUSIP numbers to be
printed on the Notes as a convenience to the Holders of the Notes. No
representation is made as to the accuracy of such numbers as printed on the
Notes and reliance may be placed only on the other identification numbers
printed hereon.
[Signature Page To Follow]
6
<PAGE>
IN WITNESS WHEREOF, the Company has caused this instrument to be duly
executed under its corporate seal this 5th day of December, 1997.
By: /s/ Robert S. Attiyeh
______________________________________
Robert S. Attiyeh
Senior Vice President, Finance and
Corporate Development, and Chief
Financial Officer
(SEAL)
TRUSTEE'S CERTIFICATE OF AUTHENTICATION:
This is one of the Securities referred to in the within-mentioned
Indenture.
Citibank, N.A.,
as Trustee
By: /s/ Wafaa Orfy
_________________________
Authorized Signatory
S-1
<PAGE>
ASSIGNMENT FORM
FOR VALUE RECEIVED, THE UNDERSIGNED HEREBY
SELLS, ASSIGNS AND TRANSFERS TO
PLEASE INSERT SOCIAL
SECURITY OR OTHER IDENTIFYING
NUMBER OF ASSIGNEE
................................................................................
................................................................................
(Please Print or Typewrite Name and Address
including Zip Code of Assignee)
................................................................................
the within Note of __________________________________ and ______________ hereby
does irrevocably constitute and appoint
................................................................................
Attorney to transfer said Note on the books of the within-named Company with
full power of substitution in the premises.
Dated: ................. .........................................
.........................................
NOTICE: The signature to this assignment must correspond with the name as it
appears on the first page of the within Note in every particular, without
alteration or enlargement or any change whatever.
Signature Guaranteed:
__________________________________
Authorized Signature
Signature guarantee should be made
by a guarantor institution
participating in the Securities
Transfer Agents Medallion Program
or in such guarantee program
acceptable to the Trustee.
A-1
